OCuSOFT Continues Expansion Into Skin Care With Zoria Cosmetic Line
Founded in 1986, OCuSOFT is a research, development and
supply company specializing in eye care. The company developed
OCuSOFT® Lid Scrub® and have crossed over into the
skin care market. Zoria™ Boost™ Lash Intensifying Serum is the
first of many new products in our new cosmetic line made especially
for individuals with sensitive eyes. Utilizing patented
polypeptide technology, Zoriaâ„¢ BoostLightPodâ„¢ naturally supports
eyelash growth and delivers noticeable results. It is available
through physicians without a prescription.
LightPod Neo
Aerolase has launched the powerful LightPod Neo XT aesthetic
laser. The breakthrough of 650-microsecond pulse
technology enables the production of high and low fluences
ranging from 4 j/cm2 to 255 j/cm2 all within this gentle
650μsec pulse duration. This avoids thermal overstressing of
the skin, eliminating treatment pain and diminishing the risk
of any adverse effects commonly caused by the previous generation
of long-pulse lasers. As a result, laser procedures can
be performed without needing to cool the skin during treatment,
even on skin of color.
Apremilast Approval Expanded to Include Plaque Psoriasis
The oral phosphodiesterase-4 inhibitor apremilast is now indicated
for the treatment of moderate to severe plaque psoriasis.
On September 23, the manufacturer, Celgene, announced that
the Food and Drug Administration had approved the expanded
indication for apremilast, which was initially approved in March
2014 for treating psoriatic arthritis. The new indication is for the
treatment of patients with moderate to severe plaque psoriasis
who are candidates for phototherapy or systemic therapy.
iCAD/Xoft System- New Axxent SPX Controller
iCAD debuted the new Axxent SPX Controller new controller
arm for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System
® at this year’s ASTRO meeting. The Axxent SPX Controller
features a streamlined design to support enhanced mobility
and flexibility for delivery of electronic brachytherapy treatment
in a wider range of healthcare settings including smaller
treatment rooms. The Axxent SPX Controller also features
new software and an enhanced bar code scanning function
that offers significant workflow benefits and improved technology
support for HIPAA compliance. These features are also
now available on the multi-platform Axxent MPX Controller,
which remains commercially available as the company’s
platform product approved for use in all indications including
breast IORT, breast APBI, skin, endometrial, and cervical
cancer treatments.
Promius Pharma Marks Milestone for the Promius Promise
Promius Pharma announced that 20,000 patients have enrolled
in the Promius Promise. The program, which is 18 months old
through September 2014, has wrapped itself around severe
recalcitrant nodular cystic acne patients and their healthcare
providers in a very meaningful way, helping patients with insurance,
as well as those without, get the care they need to treat
their severe acne. “The number of enrolled patients, 20,000, is
an indication of the important role the Promius Promise has
played in these patients’ lives and reinforces the current need
for a program designed with patient adherence in mind,†commented
Victor Caliman, Associate Director of Marketing for
Promius Pharma.
Novartis Announces FDA Advisory Committee Unanimously Recommends Approval of AIN457 (secukinumab) for Patients With Moderate to Severe Plaque Psoriasis
Novartis announced the Dermatologic and Ophthalmic Drugs
Advisory Committee (DODAC) to the US Food and Drug Administration
today voted unanimously to support the approval
of AIN457 (secukinumab), a selective interleukin-17A (IL-17A)
inhibitor, for the treatment of moderate-to-severe plaque
psoriasis in adult patients who are candidates for systemic
therapy (a drug that is absorbed into the bloodstream and
distributed to all parts of the body) or phototherapy (light
therapy). The DODAC based its recommendation on the safety
and efficacy outcomes from 10 psoriasis Phase II/III clinical
studies, which included nearly 4,000 patients with moderateto-
severe plaque psoriasis.
